Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?

Basit Öğe Kaydı
dc.contributor.authorKocak, Mehmet Zahid
dc.contributor.authorEr, Muhiddin
dc.contributor.authorUgrakli, Muzaffer
dc.contributor.authorHendem, Engin
dc.contributor.authorAraz, Murat
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T13:43:33Z
dc.date.available2024-02-23T13:43:33Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractAimDrug-drug interactions are sometimes neglected in oncology practice. Due to drug pharmacokinetic and pharmacodynamic interactions, clinically increased or decreased drug effects and increased or decreased adverse effects may occur. Considering that the concomitant use of these two drugs that affect vascular endothelial growth factor receptor (VEGFR) may cause pharmacological potentiation or additive interaction, we aimed to evaluate the survival outcomes of concomitant use of bevacizumab and beta blockers in patients with metastatic colorectal cancer (mCRC).MethodsIn total, 181 patients with mCRC administered with bevacizumab plus cytotoxic chemotherapy regimen in a first-line setting were divided into two groups: concomitant beta-blocker user and nonuser.ResultsThe median overall survival (mOS) was 35.9 (95% CI: 27.9-43.9) months in the beta-blocker-using group and 29.6 (95% CI: 27.9-43.9) months in the beta-blocker-non-using group (p = 0.054). The median progression-free survival (mPFS) was 16.1 (95% CI: 12.4-19.9) months in the beta-blocker-using group and 12.8 (95% CI: 10.6-15.0) months in the beta-blocker-non-using group (p = 0.006). The multivariate analysis revealed that beta-blocker use was an independent predictor of mPFS (HR: 0.66, 95% CI: 0.46-0.93, p = 0.018) and mOS (HR: 0.57, 95% CI: 0.36-0.91, p = 0.02).ConclusionThis study demonstrated that concomitant usage of beta blockers improved both survival outcomes, irrespective of the kind of beta blocker.en_US
dc.identifier.doi10.1007/s00228-023-03464-w
dc.identifier.endpage491en_US
dc.identifier.issn0031-6970
dc.identifier.issn1432-1041
dc.identifier.issue4en_US
dc.identifier.pmid36749352en_US
dc.identifier.scopus2-s2.0-85147586489en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage485en_US
dc.identifier.urihttps://doi.org/10.1007/s00228-023-03464-w
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10851
dc.identifier.volume79en_US
dc.identifier.wosWOS:000934209100001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofEuropean Journal Of Clinical Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBeta Blockeren_US
dc.subjectBevacizumaben_US
dc.subjectMetastasisen_US
dc.subjectColon Canceren_US
dc.titleCould the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu